作者
Shanu Modi,William Jacot,Toshinari Yamashita,Joohyuk Sohn,María Vidal,Eriko Tokunaga,Junji Tsurutani,Naoto T. Ueno,Aleix Prat,Yee Soo Chae,Keun Seok Lee,Naoki Niikura,Yeon Hee Park,Binghe Xu,Xiaojia Wang,Miguel Gil‐Gil,Wěi Li,Jean‐Yves Pierga,Seock‐Ah Im,Halle C. F. Moore,Hope S. Rugo,Rinat Yerushalmi,Flora Zagouri,Andrea Gombos,Sung‐Bae Kim,Qiang Liu,Ting Luo,Cristina Saura,Peter Schmid,Tao Sun,Dhiraj Gambhire,Lotus Yung,Yibin Wang,Jasmeet Singh,Patrik Vitazka,Gerold Meinhardt,Nadia Harbeck,David Cameron
摘要
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
爱静静
加菲丰丰
shinysparrow
寻道图强
可口可乐了
乐乐乐乐乐乐
景辣条
精明元霜
mmyhn
sirius
AireenBeryl531
星辰大海
kento
morena
丘比特
浅尝离白
Singularity
从容芮
共享精神
领导范儿
皖公网安备34019202002308
